The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...
A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...
We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...
Hosted on MSN16h
DexCom Stock Outlook: Is Wall Street Bullish or Bearish?San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback